
CLAIMS

1. Use of a GPR120 agonist of formula (I):



(I)

wherein:

R^1 is CH_3,

R^2 is H,

R^3 is selected from F, Cl and CF_3,

or

R^1 and R^2 are independently selected from substituted or unsubstituted phenyl or thiophen and H, provided that at least one of R^1 or R^2 is H, and

R^3 is F,

wherein when said phenyl or thiophen is substituted, the substituent is preferably selected from Cl, F or CH_3, more preferably in position 2, 3 or 4 on the phenyl or in position 3, 4 or 5 on the thiophen,

in the manufacture of a medicament for the prevention or treatment of inflammatory bowel disease in an individual.

2. The use of claim 1, wherein the GPR120 agonist is selected from:

7-(3-(N-(4-fluoro-2,6-dimethylphenyl)sulfamoyl) phenyl)heptanoic acid,

7-(3-(N-(4-chloro-2,6-dimethylphenyl)sulfamoyl) phenyl)heptanoic acid,

7-(3-(N-(4-trifluoromethyl-2,6-dimethyl-phenyl)sulfamoyl)phenyl)heptanoic acid,

7-(3-(N-(6-fluoro-4-methyl-[1,1'-biphenyl]-3-yl)sulfamoyl)phenyl)heptanoic acid,

7-(3-{[4-fluoro-2-methyl-5-(thiophen-2-yl)phenyl]sulfamoyl}phenyl)heptanoic acid, and

7-(3-(N-(5-fluoro-3-methyl-[1,1'-biphenyl]-2-yl)sulfamoyl)phenyl)heptanoic acid.

3. The use of claim 1 or claim 2, wherein the GPR120 agonist is 7-(3-(N-(4-chloro-2,6-dimethylphenyl)sulfamoyl) phenyl)heptanoic acid.

4. The use of any one of claims 1 to 3, wherein said inflammatory bowel disease is ulcerative colitis or Crohn's disease.

5. The use of any one of claims 1 to 4, wherein said GPR120 agonist is to be administered orally.

6. The use of any one of claims 1 to 5, wherein said GPR120 agonist is to be administered in a pharmaceutical composition that is not a controlled release formulation and/or gastro-resistant formulation.

7. Use of a pharmaceutical composition comprising the GPR120 agonist of any one of claims 1 to 3, and at least one inert pharmaceutically acceptable excipient, in the manufacture of a medicament for the prevention or treatment of inflammatory bowel disease in an individual.

8. The use of claim 7, wherein the pharmaceutical composition is to be administered orally.

9. A GPR120 agonist which is 7-(3-{[4-fluoro-2-methyl-5-(thiophen-2-yl)phenyl]sulfamoyl}phenyl)heptanoic acid.